News | November 06, 2017| Dave Fornell

No Major Differences Between PCI vs. CABG vs. Hybrid Revascularization in HREVS Study

HREVS study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia, at TCT 2017.

Study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia, explaining the HREVS trial results at TCT 2017.

No Major Differences Between PCI vs. CABG vs. Hybrid Revascularization in HREVS Study at TCT 2017.
No Major Differences Between PCI vs. CABG vs. Hybrid Revascularization in HREVS Study at TCT 2017.
No Major Differences Between PCI vs. CABG vs. Hybrid Revascularization in HREVS Study at TCT 2017.

November 6, 2017 — In the Hybrid REvascularization Versus Standards (HREVS) study that evaluated three different revascularization strategies, there was no major difference between the use of coronary artery bypass grafts (CABG), drug-eluting stent percutaneous coronary interventions (DES-PCI) or hybrid coronary revascularization (HCR) using a LIMA-LAD graft plus DES-PCI for the remaining vessels. The data from the trial was presented at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. 

Today, revascularization in multivessel coronary artery disease (MV-CAD) is achieved mainly through CABG or DES-PCI. A less-evidenced approach is the hybrid coronary revascularization (HCR). The aim of the study was to compare in a randomized trial the current guideline accepted revascularization strategy for multi-vessel coronary artery disease versus a hybrid revascularization strategy.  The single center study included 154 patients who agreed to be randomized to one of the three revascularization methods (CABG, DES-PCI or HCR). The study was powered for a primary endpoint of residual myocardial ischemia at 12 months. 

At 30 days, there were no significant differences. There was 9.6 percent (n=5) conversion to CABG in the hybrid group and higher rate of bleeding with surgery, which was expected, said study principal investigator Vladimir Ganyukov, M.D., Ph.D., head of interventional cardiology, State Scientific Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.

He said PCI was associated with the shortest hospital stay and sick-leave duration.

Major adverse events within 30 days were similar in terms of MACCE and its components. In the HCR group there were five patients (9.8 percent) who required conversion to conventional on-pump CABG with a median sternotomy either for surgical technical reasons (n=2) or due to hemodynamic instability following LIMA-LAD grafting in the absence of other lesion(s) revascularization (n=3). The HCR group was associated with a lower bleeding (for BARC 3-4) than CABG. 

At 12 months, there were no statistically significant difference s in residual ischemia. The primary study end-point of non-inferiority was met.

Target vessel of graft failure were similar across the study arms. The secondary endpoint and events at one year were comparable in the three groups. The major adverse coronary and cerebral event (MACCE) rate at 12 months was 12 percent for CABG, versus 13.4 for HCR, and 13.2 percent (p=0.83). Target vessel or graft failure rate at 12 months was 12 percent for CABG, 11.5 HCR and 11.3 for PCI (p>0.05). 

There was MACCE-free survival at 12 months was nearly identical for all three arms. 

 

Related Content

TCT 2017 Late-breaking Clinical Trial Presentations

 

Related Content

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
Overlay Init